153 related articles for article (PubMed ID: 37559519)
1. Editorial: Is vedolizumab the preferred biologic therapy for biologic-naïve patients with ulcerative colitis?
Yamamoto T
Aliment Pharmacol Ther; 2023 Sep; 58(5):546-547. PubMed ID: 37559519
[No Abstract] [Full Text] [Related]
2. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
[TBL] [Abstract][Full Text] [Related]
3. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis.
Narula N; Wong ECL; Marshall JK; Colombel JF; Dulai PS; Reinisch W
Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1588-1597.e3. PubMed ID: 34329776
[TBL] [Abstract][Full Text] [Related]
5. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
Tsai HH; Black C
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission.
Narula N; Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W
Dig Dis Sci; 2023 Jun; 68(6):2658-2666. PubMed ID: 36645636
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
Shaffer SR; Huang E; Patel S; Rubin DT
Am J Gastroenterol; 2021 Jan; 116(1):125-133. PubMed ID: 32947317
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
[TBL] [Abstract][Full Text] [Related]
11. Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis".
Attauabi M; Seidelin JB; Burisch J
Dig Liver Dis; 2023 Feb; 55(2):300-301. PubMed ID: 36464612
[No Abstract] [Full Text] [Related]
12. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
de Freitas LF; Feitosa MR; Féres O; Parra RS
Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
[No Abstract] [Full Text] [Related]
13. Should we use vedolizumab as mono or combo therapy in ulcerative colitis?
Hedin C; Halfvarson J
Best Pract Res Clin Gastroenterol; 2018; 32-33():27-34. PubMed ID: 30060935
[TBL] [Abstract][Full Text] [Related]
14. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.
Zoet ID; de Boer NK; de Meij TG
J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489
[No Abstract] [Full Text] [Related]
15. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
[TBL] [Abstract][Full Text] [Related]
16. Nodular vasculitis during treatment with vedolizumab in a patient with ulcerative colitis.
Abbenante D; Merli Y; Misciali C; Sacchelli L; Bardazzi F
Australas J Dermatol; 2022 Feb; 63(1):131-132. PubMed ID: 34817061
[No Abstract] [Full Text] [Related]
17. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
18. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
Hinojosa Del Val J; Barreiro-de Acosta M
Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
[TBL] [Abstract][Full Text] [Related]
19. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
[TBL] [Abstract][Full Text] [Related]
20. Using Vedolizumab to Treat Severe Sweet's Syndrome in a Patient With Ulcerative Colitis.
Belvis Jiménez M; Maldonado Pérez B; Argüelles-Arias F
J Crohns Colitis; 2018 Aug; 12(9):1134-1135. PubMed ID: 29788419
[No Abstract] [Full Text] [Related]
[Next] [New Search]
